Universität zu Köln

Broeckelmann, Paul J. and Engert, Andreas (2015). The GHSG Approach to Treating Hodgkin's Lymphoma. Curr. Hematol. Malig. Rep., 10 (3). S. 256 - 266. PHILADELPHIA: CURRENT MEDICINE GROUP. ISSN 1558-822X

Full text not available from this repository.

Abstract

Hodgkin's lymphoma (HL) is a relatively rare disease accounting for 15 % of all lymphoma. This disease has developed from an incurable disease to the adult malignancy with the most favorable prognosis. With current therapeutic approaches consisting of polychemo- and small-field radiotherapy, up to 80 % of all patients can be cured long term. In refractory or relapsed HL, intensified treatment including high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) is associated with progression-free survival (PFS) of 50 %. Evaluation of novel drugs in multiple relapsed or refractory cases, better treatment options for elderly patients and reducing treatment-related side effects are the main focus of current research. Recent clinical developments and future approaches in the treatment of HL will be discussed in this review.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Broeckelmann, Paul J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-394517
DOI:	10.1007/s11899-015-0262-5
Journal or Publication Title:	Curr. Hematol. Malig. Rep.
Volume:	10
Number:	3
Page Range:	S. 256 - 266
Date:	2015
Publisher:	CURRENT MEDICINE GROUP
Place of Publication:	PHILADELPHIA
ISSN:	1558-822X
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; INVOLVED-FIELD RADIOTHERAPY; POSITRON-EMISSION-TOMOGRAPHY; HIGH-DOSE CHEMOTHERAPY; COMBINED-MODALITY TREATMENT; NON-CROSS-RESISTANT; BRENTUXIMAB VEDOTIN; ELDERLY-PATIENTS; STANFORD-V; COMPREHENSIVE ANALYSIS Multiple languages Oncology; Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/39451